Skip to main content
Midas Edge

FENNEC PHARMACEUTICALS INC.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

FENC$10.83+10.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Shareholders’ Deficit

Consolidated Statements of Shareholders’ Equity (Deficit)

(U.S. dollars and shares in thousands)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Other · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · Shareholders’
​ · ​ ​ ​ · Number (Note 6) · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Deficit · ​ ​ ​ · Income · ​ ​ ​ · Deficit
​​​​​​​​​​​​​​​​​​
Balance at December 31, 2023​27,027​$144,307​$62,073​$(219,245)​$1,243​$(11,622)
Equity-based compensation - employees​—​​—​​5,061​​—​​—​​5,061
Exercise of stock options342​1,301​—​—​—​1,301
Restricted stock release158​—​(176)​—​—​(176)
Net loss—​—​—​(436)​—​(436)
Balance at December 31, 202427,527​​145,608​​66,958​​(219,681)​​1,243​​(5,872)
Equity-based compensation - employees—​—​7,033​—​—​7,033
Issuance of common stock, net of offering costs​6,037​​42,049​​—​​—​​—​​42,049
Warrant exercise​9​​59​​(59)​​—​​—​​—
Exercise of stock options400​2,190​—​—​—​2,190
Restricted stock release​190​​—​​(187)​​—​​—​​(187)
Net loss—​—​—​(9,741)​—​(9,741)
Balance at December 31, 202534,163​$189,906​$73,745​$(229,422)​$1,243​$35,472
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.